{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:00:51Z","timestamp":1775743251014,"version":"3.50.1"},"reference-count":140,"publisher":"Harborside Press, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:p>Thymic epithelial tumors (TETs) are rare malignancies originating from thymic epithelial cells, comprising thymomas and thymic carcinomas. The heterogeneity of TETs poses significant diagnostic and therapeutic challenges, necessitating the identification of reliable biomarkers to improve classification and treatment stratification. The integration of multiomic approaches and artificial intelligence are transforming biomarker discovery, offering new insights into TET pathogenesis and therapeutic vulnerabilities. However, clinical translation of these biomarkers remains limited due to the rarity of these diseases, emphasizing the need for collaborative efforts to accelerate the development of novel therapeutics. Future research focusing on biomarker-driven precision medicine will be essential for enhancing risk stratification and advancing targeted therapeutic strategies in TET management.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7086","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:37:29Z","timestamp":1773088649000},"source":"Crossref","is-referenced-by-count":0,"title":["Potential Biomarkers in Thymic Epithelial Tumors: Thymoma and Thymic Carcinoma"],"prefix":"10.6004","volume":"24","author":[{"given":"Rohan","family":"Maniar","sequence":"first","affiliation":[{"name":"Division of Hematology & Oncology, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J.","family":"Loehrer","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Front Oncol","first-page":"1308989","article-title":"Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019","volume":"13","author":"Gerber TS","year":"2023","unstructured":"Gerber TS, Strobl S, Marx A,  Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019. Front Oncol 2023;13:1308989."},{"key":"B2","series-title":"N Engl J Med","first-page":"406","article-title":"Health consequences of thymus removal in adults","volume":"389","author":"Kooshesh KA","year":"2023","unstructured":"Kooshesh KA, Foy BH, Sykes DB,  Health consequences of thymus removal in adults. N Engl J Med 2023;389:406\u2013417."},{"key":"B3","series-title":"Nat Immunol","first-page":"1593","article-title":"Age-related epithelial defects limit thymic function and regeneration","volume":"25","author":"Kousa AI","year":"2024","unstructured":"Kousa AI, Jahn L, Zhao K,  Age-related epithelial defects limit thymic function and regeneration. Nat Immunol 2024;25:1593\u20131606."},{"key":"B4","series-title":"J Thorac Cardiovasc Surg","first-page":"787","article-title":"Does thymectomy in adults have long-term health consequences?","volume":"169","author":"Detterbeck FC","year":"2025","unstructured":"Detterbeck FC, Kaminski HJ, Blasberg JD, O\u2019Connor KC. Does thymectomy in adults have long-term health consequences? J Thorac Cardiovasc Surg 2025;169:787\u2013795.e2."},{"key":"B5","series-title":"Curr Treat Options Oncol","first-page":"62","article-title":"Paraneoplastic and therapy-related immune complications in thymic malignancies","volume":"20","author":"Lippner EA","year":"2019","unstructured":"Lippner EA, Lewis DB, Robinson WH, Katsumoto TR. Paraneoplastic and therapy-related immune complications in thymic malignancies. Curr Treat Options Oncol 2019;20:62."},{"key":"B6","series-title":"Autoimmun Rev","first-page":"875","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx A","year":"2013","unstructured":"Marx A, Pfister F, Schalke B,  The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013;12:875\u2013884."},{"key":"B7","series-title":"J Thorac Oncol","first-page":"S137","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler B","year":"2014","unstructured":"Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol 2014;9(Suppl 2):S137\u2013142."},{"key":"B8","series-title":"J Thorac Dis","first-page":"2842","article-title":"Myasthenia gravis as a prognostic marker in patients with thymoma","volume":"10","author":"Cacho-D\u00edaz B","year":"2018","unstructured":"Cacho-D\u00edaz B, Salmer\u00f3n-Moreno K, Lorenzana-Mendoza NA,  Myasthenia gravis as a prognostic marker in patients with thymoma. J Thorac Dis 2018;10:2842\u20132848."},{"key":"B9","series-title":"J Clin Neurol","first-page":"161","article-title":"Incidence of thymoma in myasthenia gravis: a systematic review","volume":"8","author":"Mao ZF","year":"2012","unstructured":"Mao ZF, Mo XA, Qin C,  Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol 2012;8:161\u2013169."},{"key":"B10","author":"Rosai J","year":"1999","unstructured":"Rosai J, Sobin LH. Histological Typing of Tumours of the Thymus, 2nd ed. Springer; 1999."},{"key":"B11","series-title":"J Thorac Oncol","first-page":"200","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx A","year":"2022","unstructured":"Marx A, Chan JKC, Chalabreysse L,  The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022;17:200\u2013213."},{"key":"B12","series-title":"Cancers (Basel)","first-page":"416","article-title":"What have we learned from molecularly informed clinical trials on thymomas and thymic carcinomas\u2013current status and future directions?","volume":"16","author":"Maniar R","year":"2024","unstructured":"Maniar R, Loehrer PJ. What have we learned from molecularly informed clinical trials on thymomas and thymic carcinomas\u2013current status and future directions? Cancers (Basel) 2024;16:416."},{"key":"B13","series-title":"Cancer Cell","first-page":"244","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich M","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I,  The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018;33:244\u2013258.e10."},{"key":"B14","series-title":"Nat Commun","first-page":"5463","article-title":"The immune landscape of human thymic epithelial tumors","volume":"13","author":"Xin Z","year":"2022","unstructured":"Xin Z, Lin M, Hao Z,  The immune landscape of human thymic epithelial tumors. Nat Commun 2022;13:5463."},{"key":"B15","series-title":"Nat Rev Clin Oncol","first-page":"229","article-title":"Rare molecular subtypes of lung cancer","volume":"20","author":"Harada G","year":"2023","unstructured":"Harada G, Yang SR, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol 2023;20:229\u2013249."},{"key":"B16","series-title":"Cancer Cell","first-page":"346","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay CM","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM,  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021;39:346\u2013360.e7."},{"key":"B17","series-title":"J Thorac Cardiovasc Surg","first-page":"26","article-title":"Comparison of patterns of relapse in thymic carcinoma and thymoma","volume":"138","author":"Huang J","year":"2009","unstructured":"Huang J, Rizk NP, Travis WD,  Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg 2009;138:26\u201331."},{"key":"B18","series-title":"J Thorac Oncol","first-page":"109","article-title":"Thymoma: a population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano C","year":"2013","unstructured":"Mariano C, Ionescu DN, Cheung WY,  Thymoma: a population-based study of the management and outcomes for the province of British Columbia. J Thorac Oncol 2013;8:109\u2013117."},{"key":"B19","series-title":"J Clin Oncol","first-page":"1501","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Str\u00f6bel P","year":"2004","unstructured":"Str\u00f6bel P, Bauer A, Puppe B,  Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501\u20131509."},{"key":"B20","series-title":"Thorac Cancer","first-page":"3242","article-title":"Prognostic factors and genetic markers in thymic epithelial tumors: a narrative review","volume":"13","author":"Agrafiotis AC","year":"2022","unstructured":"Agrafiotis AC, Siozopoulou V, Hendriks JMH,  Prognostic factors and genetic markers in thymic epithelial tumors: a narrative review. Thorac Cancer 2022;13:3242\u20133249."},{"key":"B21","series-title":"Mediastinum","first-page":"36","article-title":"The role of induction therapy for thymic malignancies: a narrative review","volume":"4","author":"Patel DC","year":"2020","unstructured":"Patel DC, Shrager JB, Padda SK. The role of induction therapy for thymic malignancies: a narrative review. Mediastinum 2020;4:36."},{"key":"B22","series-title":"Ann Thorac Surg","first-page":"1848","article-title":"A meta-analysis of induction therapy for advanced thymic epithelial tumors","volume":"99","author":"Hamaji M","year":"2015","unstructured":"Hamaji M, Ali SO, Burt BM. A meta-analysis of induction therapy for advanced thymic epithelial tumors. Ann Thorac Surg 2015;99:1848\u20131856."},{"key":"B23","series-title":"Ann Thorac Surg","first-page":"355","article-title":"Comparison of neoadjuvant chemotherapy followed by surgery to upfront surgery for thymic malignancy","volume":"107","author":"Park S","year":"2019","unstructured":"Park S, Park IK, Kim YT,  Comparison of neoadjuvant chemotherapy followed by surgery to upfront surgery for thymic malignancy. Ann Thorac Surg 2019;107:355\u2013362."},{"key":"B24","series-title":"Ann Thorac Surg","first-page":"385","article-title":"Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors","volume":"85","author":"Wright CD","year":"2008","unstructured":"Wright CD, Choi NC, Wain JC,  Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008;85:385\u2013389."},{"key":"B25","series-title":"J Thorac Cardiovasc Surg","first-page":"36","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial","volume":"147","author":"Korst RJ","year":"2014","unstructured":"Korst RJ, Bezjak A, Blackmon S,  Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg 2014;147:36\u201344, 46.e1."},{"key":"B26","series-title":"ESMO Open","first-page":"101627","article-title":"Genomic characterization of thymic epithelial tumors in a real-world dataset","volume":"8","author":"Kurokawa K","year":"2023","unstructured":"Kurokawa K, Shukuya T, Greenstein RA,  Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open 2023;8:101627."},{"key":"B27","series-title":"Nat Med","first-page":"3100","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux C","year":"2023","unstructured":"Fenioux C, Abbar B, Boussouar S,  Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 2023;29:3100\u20133110."},{"key":"B28","series-title":"Chin J Cancer Res","first-page":"563","article-title":"Integrating pathomics with radiomics and genomics for cancer prognosis: a brief review","volume":"33","author":"Lu C","year":"2021","unstructured":"Lu C, Shiradkar R, Liu Z. Integrating pathomics with radiomics and genomics for cancer prognosis: a brief review. Chin J Cancer Res 2021;33:563\u2013573."},{"key":"B29","series-title":"J Thorac Dis","first-page":"1342","article-title":"CT-based radiomics analysis for differentiation between thymoma and thymic carcinoma","volume":"14","author":"Ohira R","year":"2022","unstructured":"Ohira R, Yanagawa M, Suzuki Y,  CT-based radiomics analysis for differentiation between thymoma and thymic carcinoma. J Thorac Dis 2022;14:1342\u20131352."},{"key":"B30","series-title":"AJR Am J Roentgenol","first-page":"328","article-title":"MRI radiomics analysis for predicting the pathologic classification and TNM staging of thymic epithelial tumors: a pilot study","volume":"214","author":"Xiao G","year":"2020","unstructured":"Xiao G, Rong WC, Hu YC,  MRI radiomics analysis for predicting the pathologic classification and TNM staging of thymic epithelial tumors: a pilot study. AJR Am J Roentgenol 2020;214:328\u2013340."},{"key":"B31","series-title":"Front Oncol","first-page":"628534","article-title":"CT-based radiomics signatures for predicting the risk categorization of thymic epithelial tumors","volume":"11","author":"Liu J","year":"2021","unstructured":"Liu J, Yin P, Wang S,  CT-based radiomics signatures for predicting the risk categorization of thymic epithelial tumors. Front Oncol 2021;11:628534."},{"key":"B32","series-title":"Ann Thorac Surg","first-page":"957","article-title":"CT radiomic features for predicting resectability and TNM staging in thymic epithelial tumors","volume":"113","author":"Araujo-Filho JAB","year":"2022","unstructured":"Araujo-Filho JAB, Mayoral M, Zheng J,  CT radiomic features for predicting resectability and TNM staging in thymic epithelial tumors. Ann Thorac Surg 2022;113:957\u2013965."},{"key":"B33","article-title":"NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1.2025","author":"Riely GJ","unstructured":"Riely GJ, Wood DE, Aisner DL, . NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1.2025. Accessed February 25, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B34","series-title":"PLoS One","first-page":"e66047","article-title":"A gene signature to determine metastatic behavior in thymomas","volume":"8","author":"G\u00f6kmen-Polar Y","year":"2013","unstructured":"G\u00f6kmen-Polar Y, Cook RW, Goswami CP,  A gene signature to determine metastatic behavior in thymomas. PLoS One 2013;8:e66047."},{"key":"B35","series-title":"N Engl J Med","first-page":"111","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano JA","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF,  Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111\u2013121."},{"key":"B36","series-title":"Front Genet","first-page":"1172108","article-title":"Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review","volume":"14","author":"Zhu L","year":"2023","unstructured":"Zhu L, Xu R, Yang L,  Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review. Front Genet 2023;14:1172108."},{"key":"B37","series-title":"Front Oncol","first-page":"602153","article-title":"A new horizon of liquid biopsy in thymic epithelial tumors: the potential utility of circulating cell-free DNA","volume":"10","author":"Ottaviano M","year":"2020","unstructured":"Ottaviano M, Giuliano M, Tortora M,  A new horizon of liquid biopsy in thymic epithelial tumors: the potential utility of circulating cell-free DNA. Front Oncol 2020;10:602153."},{"key":"B38","series-title":"J Clin Oncol","first-page":"8577","article-title":"Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs)","volume":"39(Suppl)","author":"Dada HI","year":"2021","unstructured":"Dada HI, Drusbosky L, Giaccone G. Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs). J Clin Oncol 2021;39(Suppl):Abstract 8577."},{"key":"B39","series-title":"J Clin Oncol","first-page":"8598","article-title":"Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors","volume":"41(Suppl)","author":"Ardeshir-Larijani F","year":"2023","unstructured":"Ardeshir-Larijani F, Ravichandran KR, Schneider BP,  Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors. J Clin Oncol 2023;41(Suppl):Abstract 8598."},{"key":"B40","series-title":"N Engl J Med","first-page":"2261","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie J","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K,  Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386:2261\u20132272."},{"key":"B41","series-title":"J Liq Biopsy","first-page":"100007","article-title":"Circulating tumor DNA in clinical trials for solid tumors: challenges and current applications","volume":"1","author":"Parisi C","year":"2023","unstructured":"Parisi C, Tagliamento M, Belcaid L,  Circulating tumor DNA in clinical trials for solid tumors: challenges and current applications. J Liq Biopsy 2023;1:100007."},{"key":"B42","series-title":"Oncologist","first-page":"919","article-title":"Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers","volume":"27","author":"Girard N","year":"2022","unstructured":"Girard N, Basse C, Schrock A,  Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist 2022;27:919\u2013929."},{"key":"B43","series-title":"Oncotarget","first-page":"1178","article-title":"Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type thymic epithelial tumor; thymoma; genomics; clustering; computational analysis","volume":"12","author":"Padda SK","year":"2021","unstructured":"Padda SK, G\u00f6kmen-Polar Y, Hellyer JA,  Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type thymic epithelial tumor; thymoma; genomics; clustering; computational analysis. Oncotarget 2021;12:1178\u20131186."},{"key":"B44","series-title":"JCO Precis Oncol","first-page":"e2200465","article-title":"Clinicogenomic landscape of metastatic thymic epithelial tumors","volume":"7","author":"Ardeshir-Larijani F","year":"2023","unstructured":"Ardeshir-Larijani F, Schneider BP, Althouse SK,  Clinicogenomic landscape of metastatic thymic epithelial tumors. JCO Precis Oncol 2023;7:e2200465."},{"key":"B45","series-title":"Lung Cancer","first-page":"107324","article-title":"High levels of expression of Trop-2 in thymic epithelial tumors","volume":"184","author":"Yeung V","year":"2023","unstructured":"Yeung V, Zaemes J, Yeh J,  High levels of expression of Trop-2 in thymic epithelial tumors. Lung Cancer 2023;184:107324."},{"key":"B46","series-title":"Clin Lung Cancer","first-page":"180","article-title":"Trop-2 expression and its impact on survival in thymic epithelial tumors: brief report","volume":"25","author":"Ardeshir-Larijani F","year":"2024","unstructured":"Ardeshir-Larijani F, Maniar R, Goyal S,  Trop-2 expression and its impact on survival in thymic epithelial tumors: brief report. Clin Lung Cancer 2024;25:180\u2013185.e1."},{"key":"B47","series-title":"J Thorac Oncol","first-page":"S280","article-title":"P2.14B.03 A phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma and thymic carcinoma","volume":"19(Suppl)","author":"Marks JA","year":"2024","unstructured":"Marks JA, Agarwal S, Ahn J,  P2.14B.03 A phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma and thymic carcinoma. J Thorac Oncol 2024;19(Suppl):S280."},{"key":"B48","series-title":"J Clin Oncol","first-page":"8113","article-title":"Comprehensive molecular characterization of thymic epithelial tumors","volume":"42(Suppl)","author":"Kim C","year":"2024","unstructured":"Kim C, Adeyelu TT, Maniar R,  Comprehensive molecular characterization of thymic epithelial tumors. J Clin Oncol 2024;42(Suppl):Abstract 8113."},{"key":"B49","series-title":"Mediastinum","first-page":"AB060","article-title":"AB060. Multiplex immunofluorescence analysis of potential targets in thymic epithelial tumors","volume":"8","author":"Aggarwal V","year":"2024","unstructured":"Aggarwal V, Modepalli S, Ahn J,  AB060. Multiplex immunofluorescence analysis of potential targets in thymic epithelial tumors. Mediastinum 2024;8:AB060."},{"key":"B50","series-title":"Cancers (Basel)","first-page":"2299","article-title":"CD117, BAP1, MTAP, and TdT is a useful immunohistochemical panel to distinguish thymoma from thymic carcinoma","volume":"14","author":"Angirekula M","year":"2022","unstructured":"Angirekula M, Chang SY, Jenkins SM,  CD117, BAP1, MTAP, and TdT is a useful immunohistochemical panel to distinguish thymoma from thymic carcinoma. Cancers (Basel) 2022;14:2299."},{"key":"B51","series-title":"Cancers (Basel)","first-page":"2274","article-title":"EZH2 and POU2F3 can aid in the distinction of thymic carcinoma from thymoma","volume":"15","author":"Naso JR","year":"2023","unstructured":"Naso JR, Vrana JA, Koepplin JW,  EZH2 and POU2F3 can aid in the distinction of thymic carcinoma from thymoma. Cancers (Basel) 2023;15:2274."},{"key":"B52","series-title":"J Transl Med","first-page":"620","article-title":"MTAP loss: a possible therapeutic approach for glioblastoma","volume":"20","author":"Patro CPK","year":"2022","unstructured":"Patro CPK, Biswas N, Pingle SC,  MTAP loss: a possible therapeutic approach for glioblastoma. J Transl Med 2022;20:620."},{"key":"B53","series-title":"Ann Oncol","first-page":"1138","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon J","year":"2024","unstructured":"Rodon J, Prenen H, Sacher A,  First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol 2024;35:1138\u20131147."},{"key":"B54","series-title":"J Clin Oncol","first-page":"3011","article-title":"BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007","volume":"43(Suppl)","author":"Arbour KC","year":"2025","unstructured":"Arbour KC, George B, Henry JT,  BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007. J Clin Oncol 2025;43(Suppl):Abstract 3011."},{"key":"B55","series-title":"Ann Oncol","first-page":"817","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto C","year":"2024","unstructured":"Proto C, Ganzinelli M, Manglaviti S,  Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Ann Oncol 2024;35:817\u2013826."},{"key":"B56","series-title":"Signal Transduct Target Ther","first-page":"262","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder S","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther 2023;8:262."},{"key":"B57","series-title":"Lung Cancer","first-page":"154","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya Y","year":"2015","unstructured":"Katsuya Y, Fujita Y, Horinouchi H,  Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 2015;88:154\u2013159."},{"key":"B58","series-title":"PLoS One","first-page":"e0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour KC","year":"2017","unstructured":"Arbour KC, Naidoo J, Steele KE,  Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS One 2017;12:e0182665."},{"key":"B59","series-title":"J Thorac Oncol","first-page":"1204","article-title":"Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma","volume":"13","author":"Owen D","year":"2018","unstructured":"Owen D, Chu B, Lehman AM,  Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma. J Thorac Oncol 2018;13:1204\u20131212."},{"key":"B60","series-title":"J Thorac Oncol","first-page":"500","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda SK","year":"2015","unstructured":"Padda SK, Riess JW, Schwartz EJ,  Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol 2015;10:500\u2013508."},{"key":"B61","series-title":"Eur J Cancer","first-page":"78","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya Y","year":"2019","unstructured":"Katsuya Y, Horinouchi H, Seto T,  Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 2019;113:78\u201386."},{"key":"B62","series-title":"J Clin Oncol","first-page":"2162","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho J","year":"2019","unstructured":"Cho J, Kim HS, Ku BM,  Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol 2019;37:2162\u20132170."},{"key":"B63","series-title":"Lancet Oncol","first-page":"347","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone G","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J,  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018;19:347\u2013355."},{"key":"B64","series-title":"J Thorac Oncol","first-page":"483","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone G","year":"2021","unstructured":"Giaccone G, Kim C. Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up. J Thorac Oncol 2021;16:483\u2013485."},{"key":"B65","series-title":"J Immunother Cancer","first-page":"269","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan A","year":"2019","unstructured":"Rajan A, Heery CR, Thomas A,  Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma. J Immunother Cancer 2019;7:269."},{"key":"B66","series-title":"ESMO Open","first-page":"101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard N","year":"2023","unstructured":"Girard N, Ponce Aix S, Cedres S,  Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 2023;8:101576."},{"key":"B67","series-title":"Eur J Cancer","first-page":"117","article-title":"Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis","volume":"180","author":"Remon J","year":"2023","unstructured":"Remon J, Villacampa G, Facchinetti F,  Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis. Eur J Cancer 2023;180:117\u2013124."},{"key":"B68","series-title":"Cell Rep Med","first-page":"100392","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He Y","year":"2021","unstructured":"He Y, Ramesh A, Gusev Y,  Molecular predictors of response to pembrolizumab in thymic carcinoma. Cell Rep Med 2021;2:100392."},{"key":"B69","series-title":"Ann Rheum Dis","first-page":"150","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen AL","year":"2019","unstructured":"Mammen AL, Rajan A, Pak K,  Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 2019;78:150\u2013152."},{"key":"B70","series-title":"Comput Biol Med","first-page":"109488","article-title":"Unraveling the complexities of immunotherapy for thymic epithelial tumors via bioinformatics and experimental analyses","volume":"185","author":"Zhang G","year":"2025","unstructured":"Zhang G, Yu Q, Chen X,  Unraveling the complexities of immunotherapy for thymic epithelial tumors via bioinformatics and experimental analyses. Comput Biol Med 2025;185:109488."},{"key":"B1","series-title":"Front Oncol","first-page":"1308989","article-title":"Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019","volume":"13","author":"Gerber TS","year":"2023","unstructured":"Gerber TS, Strobl S, Marx A,  Epidemiology of thymomas and thymic carcinomas in the United States and Germany, 1999\u20132019. Front Oncol 2023;13:1308989."},{"key":"B2","series-title":"N Engl J Med","first-page":"406","article-title":"Health consequences of thymus removal in adults","volume":"389","author":"Kooshesh KA","year":"2023","unstructured":"Kooshesh KA, Foy BH, Sykes DB,  Health consequences of thymus removal in adults. N Engl J Med 2023;389:406\u2013417."},{"key":"B3","series-title":"Nat Immunol","first-page":"1593","article-title":"Age-related epithelial defects limit thymic function and regeneration","volume":"25","author":"Kousa AI","year":"2024","unstructured":"Kousa AI, Jahn L, Zhao K,  Age-related epithelial defects limit thymic function and regeneration. Nat Immunol 2024;25:1593\u20131606."},{"key":"B4","series-title":"J Thorac Cardiovasc Surg","first-page":"787","article-title":"Does thymectomy in adults have long-term health consequences?","volume":"169","author":"Detterbeck FC","year":"2025","unstructured":"Detterbeck FC, Kaminski HJ, Blasberg JD, O\u2019Connor KC. Does thymectomy in adults have long-term health consequences? J Thorac Cardiovasc Surg 2025;169:787\u2013795.e2."},{"key":"B5","series-title":"Curr Treat Options Oncol","first-page":"62","article-title":"Paraneoplastic and therapy-related immune complications in thymic malignancies","volume":"20","author":"Lippner EA","year":"2019","unstructured":"Lippner EA, Lewis DB, Robinson WH, Katsumoto TR. Paraneoplastic and therapy-related immune complications in thymic malignancies. Curr Treat Options Oncol 2019;20:62."},{"key":"B6","series-title":"Autoimmun Rev","first-page":"875","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx A","year":"2013","unstructured":"Marx A, Pfister F, Schalke B,  The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013;12:875\u2013884."},{"key":"B7","series-title":"J Thorac Oncol","first-page":"S137","article-title":"Alterations of the immune system in thymic malignancies","volume":"9","author":"Weksler B","year":"2014","unstructured":"Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol 2014;9(Suppl 2):S137\u2013142."},{"key":"B8","series-title":"J Thorac Dis","first-page":"2842","article-title":"Myasthenia gravis as a prognostic marker in patients with thymoma","volume":"10","author":"Cacho-D\u00edaz B","year":"2018","unstructured":"Cacho-D\u00edaz B, Salmer\u00f3n-Moreno K, Lorenzana-Mendoza NA,  Myasthenia gravis as a prognostic marker in patients with thymoma. J Thorac Dis 2018;10:2842\u20132848."},{"key":"B9","series-title":"J Clin Neurol","first-page":"161","article-title":"Incidence of thymoma in myasthenia gravis: a systematic review","volume":"8","author":"Mao ZF","year":"2012","unstructured":"Mao ZF, Mo XA, Qin C,  Incidence of thymoma in myasthenia gravis: a systematic review. J Clin Neurol 2012;8:161\u2013169."},{"key":"B10","author":"Rosai J","year":"1999","unstructured":"Rosai J, Sobin LH. Histological Typing of Tumours of the Thymus, 2nd ed. Springer; 1999."},{"key":"B11","series-title":"J Thorac Oncol","first-page":"200","article-title":"The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors?","volume":"17","author":"Marx A","year":"2022","unstructured":"Marx A, Chan JKC, Chalabreysse L,  The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022;17:200\u2013213."},{"key":"B12","series-title":"Cancers (Basel)","first-page":"416","article-title":"What have we learned from molecularly informed clinical trials on thymomas and thymic carcinomas\u2013current status and future directions?","volume":"16","author":"Maniar R","year":"2024","unstructured":"Maniar R, Loehrer PJ. What have we learned from molecularly informed clinical trials on thymomas and thymic carcinomas\u2013current status and future directions? Cancers (Basel) 2024;16:416."},{"key":"B13","series-title":"Cancer Cell","first-page":"244","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich M","year":"2018","unstructured":"Radovich M, Pickering CR, Felau I,  The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018;33:244\u2013258.e10."},{"key":"B14","series-title":"Nat Commun","first-page":"5463","article-title":"The immune landscape of human thymic epithelial tumors","volume":"13","author":"Xin Z","year":"2022","unstructured":"Xin Z, Lin M, Hao Z,  The immune landscape of human thymic epithelial tumors. Nat Commun 2022;13:5463."},{"key":"B15","series-title":"Nat Rev Clin Oncol","first-page":"229","article-title":"Rare molecular subtypes of lung cancer","volume":"20","author":"Harada G","year":"2023","unstructured":"Harada G, Yang SR, Cocco E, Drilon A. Rare molecular subtypes of lung cancer. Nat Rev Clin Oncol 2023;20:229\u2013249."},{"key":"B16","series-title":"Cancer Cell","first-page":"346","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay CM","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM,  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 2021;39:346\u2013360.e7."},{"key":"B17","series-title":"J Thorac Cardiovasc Surg","first-page":"26","article-title":"Comparison of patterns of relapse in thymic carcinoma and thymoma","volume":"138","author":"Huang J","year":"2009","unstructured":"Huang J, Rizk NP, Travis WD,  Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg 2009;138:26\u201331."},{"key":"B18","series-title":"J Thorac Oncol","first-page":"109","article-title":"Thymoma: a population-based study of the management and outcomes for the province of British Columbia","volume":"8","author":"Mariano C","year":"2013","unstructured":"Mariano C, Ionescu DN, Cheung WY,  Thymoma: a population-based study of the management and outcomes for the province of British Columbia. J Thorac Oncol 2013;8:109\u2013117."},{"key":"B19","series-title":"J Clin Oncol","first-page":"1501","article-title":"Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis","volume":"22","author":"Str\u00f6bel P","year":"2004","unstructured":"Str\u00f6bel P, Bauer A, Puppe B,  Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501\u20131509."},{"key":"B20","series-title":"Thorac Cancer","first-page":"3242","article-title":"Prognostic factors and genetic markers in thymic epithelial tumors: a narrative review","volume":"13","author":"Agrafiotis AC","year":"2022","unstructured":"Agrafiotis AC, Siozopoulou V, Hendriks JMH,  Prognostic factors and genetic markers in thymic epithelial tumors: a narrative review. Thorac Cancer 2022;13:3242\u20133249."},{"key":"B21","series-title":"Mediastinum","first-page":"36","article-title":"The role of induction therapy for thymic malignancies: a narrative review","volume":"4","author":"Patel DC","year":"2020","unstructured":"Patel DC, Shrager JB, Padda SK. The role of induction therapy for thymic malignancies: a narrative review. Mediastinum 2020;4:36."},{"key":"B22","series-title":"Ann Thorac Surg","first-page":"1848","article-title":"A meta-analysis of induction therapy for advanced thymic epithelial tumors","volume":"99","author":"Hamaji M","year":"2015","unstructured":"Hamaji M, Ali SO, Burt BM. A meta-analysis of induction therapy for advanced thymic epithelial tumors. Ann Thorac Surg 2015;99:1848\u20131856."},{"key":"B23","series-title":"Ann Thorac Surg","first-page":"355","article-title":"Comparison of neoadjuvant chemotherapy followed by surgery to upfront surgery for thymic malignancy","volume":"107","author":"Park S","year":"2019","unstructured":"Park S, Park IK, Kim YT,  Comparison of neoadjuvant chemotherapy followed by surgery to upfront surgery for thymic malignancy. Ann Thorac Surg 2019;107:355\u2013362."},{"key":"B24","series-title":"Ann Thorac Surg","first-page":"385","article-title":"Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors","volume":"85","author":"Wright CD","year":"2008","unstructured":"Wright CD, Choi NC, Wain JC,  Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg 2008;85:385\u2013389."},{"key":"B25","series-title":"J Thorac Cardiovasc Surg","first-page":"36","article-title":"Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial","volume":"147","author":"Korst RJ","year":"2014","unstructured":"Korst RJ, Bezjak A, Blackmon S,  Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg 2014;147:36\u201344, 46.e1."},{"key":"B26","series-title":"ESMO Open","first-page":"101627","article-title":"Genomic characterization of thymic epithelial tumors in a real-world dataset","volume":"8","author":"Kurokawa K","year":"2023","unstructured":"Kurokawa K, Shukuya T, Greenstein RA,  Genomic characterization of thymic epithelial tumors in a real-world dataset. ESMO Open 2023;8:101627."},{"key":"B27","series-title":"Nat Med","first-page":"3100","article-title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","volume":"29","author":"Fenioux C","year":"2023","unstructured":"Fenioux C, Abbar B, Boussouar S,  Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat Med 2023;29:3100\u20133110."},{"key":"B28","series-title":"Chin J Cancer Res","first-page":"563","article-title":"Integrating pathomics with radiomics and genomics for cancer prognosis: a brief review","volume":"33","author":"Lu C","year":"2021","unstructured":"Lu C, Shiradkar R, Liu Z. Integrating pathomics with radiomics and genomics for cancer prognosis: a brief review. Chin J Cancer Res 2021;33:563\u2013573."},{"key":"B29","series-title":"J Thorac Dis","first-page":"1342","article-title":"CT-based radiomics analysis for differentiation between thymoma and thymic carcinoma","volume":"14","author":"Ohira R","year":"2022","unstructured":"Ohira R, Yanagawa M, Suzuki Y,  CT-based radiomics analysis for differentiation between thymoma and thymic carcinoma. J Thorac Dis 2022;14:1342\u20131352."},{"key":"B30","series-title":"AJR Am J Roentgenol","first-page":"328","article-title":"MRI radiomics analysis for predicting the pathologic classification and TNM staging of thymic epithelial tumors: a pilot study","volume":"214","author":"Xiao G","year":"2020","unstructured":"Xiao G, Rong WC, Hu YC,  MRI radiomics analysis for predicting the pathologic classification and TNM staging of thymic epithelial tumors: a pilot study. AJR Am J Roentgenol 2020;214:328\u2013340."},{"key":"B31","series-title":"Front Oncol","first-page":"628534","article-title":"CT-based radiomics signatures for predicting the risk categorization of thymic epithelial tumors","volume":"11","author":"Liu J","year":"2021","unstructured":"Liu J, Yin P, Wang S,  CT-based radiomics signatures for predicting the risk categorization of thymic epithelial tumors. Front Oncol 2021;11:628534."},{"key":"B32","series-title":"Ann Thorac Surg","first-page":"957","article-title":"CT radiomic features for predicting resectability and TNM staging in thymic epithelial tumors","volume":"113","author":"Araujo-Filho JAB","year":"2022","unstructured":"Araujo-Filho JAB, Mayoral M, Zheng J,  CT radiomic features for predicting resectability and TNM staging in thymic epithelial tumors. Ann Thorac Surg 2022;113:957\u2013965."},{"key":"B33","article-title":"NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1.2025","author":"Riely GJ","unstructured":"Riely GJ, Wood DE, Aisner DL, . NCCN Clinical Practice Guidelines in Oncology: Thymomas and Thymic Carcinomas. Version 1.2025. Accessed February 25, 2025. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B34","series-title":"PLoS One","first-page":"e66047","article-title":"A gene signature to determine metastatic behavior in thymomas","volume":"8","author":"G\u00f6kmen-Polar Y","year":"2013","unstructured":"G\u00f6kmen-Polar Y, Cook RW, Goswami CP,  A gene signature to determine metastatic behavior in thymomas. PLoS One 2013;8:e66047."},{"key":"B35","series-title":"N Engl J Med","first-page":"111","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano JA","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF,  Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 2018;379:111\u2013121."},{"key":"B36","series-title":"Front Genet","first-page":"1172108","article-title":"Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review","volume":"14","author":"Zhu L","year":"2023","unstructured":"Zhu L, Xu R, Yang L,  Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review. Front Genet 2023;14:1172108."},{"key":"B37","series-title":"Front Oncol","first-page":"602153","article-title":"A new horizon of liquid biopsy in thymic epithelial tumors: the potential utility of circulating cell-free DNA","volume":"10","author":"Ottaviano M","year":"2020","unstructured":"Ottaviano M, Giuliano M, Tortora M,  A new horizon of liquid biopsy in thymic epithelial tumors: the potential utility of circulating cell-free DNA. Front Oncol 2020;10:602153."},{"key":"B38","series-title":"J Clin Oncol","first-page":"8577","article-title":"Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs)","volume":"39(Suppl)","author":"Dada HI","year":"2021","unstructured":"Dada HI, Drusbosky L, Giaccone G. Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs). J Clin Oncol 2021;39(Suppl):Abstract 8577."},{"key":"B39","series-title":"J Clin Oncol","first-page":"8598","article-title":"Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors","volume":"41(Suppl)","author":"Ardeshir-Larijani F","year":"2023","unstructured":"Ardeshir-Larijani F, Ravichandran KR, Schneider BP,  Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors. J Clin Oncol 2023;41(Suppl):Abstract 8598."},{"key":"B40","series-title":"N Engl J Med","first-page":"2261","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie J","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K,  Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med 2022;386:2261\u20132272."},{"key":"B41","series-title":"J Liq Biopsy","first-page":"100007","article-title":"Circulating tumor DNA in clinical trials for solid tumors: challenges and current applications","volume":"1","author":"Parisi C","year":"2023","unstructured":"Parisi C, Tagliamento M, Belcaid L,  Circulating tumor DNA in clinical trials for solid tumors: challenges and current applications. J Liq Biopsy 2023;1:100007."},{"key":"B42","series-title":"Oncologist","first-page":"919","article-title":"Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers","volume":"27","author":"Girard N","year":"2022","unstructured":"Girard N, Basse C, Schrock A,  Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist 2022;27:919\u2013929."},{"key":"B43","series-title":"Oncotarget","first-page":"1178","article-title":"Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type thymic epithelial tumor; thymoma; genomics; clustering; computational analysis","volume":"12","author":"Padda SK","year":"2021","unstructured":"Padda SK, G\u00f6kmen-Polar Y, Hellyer JA,  Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type thymic epithelial tumor; thymoma; genomics; clustering; computational analysis. Oncotarget 2021;12:1178\u20131186."},{"key":"B44","series-title":"JCO Precis Oncol","first-page":"e2200465","article-title":"Clinicogenomic landscape of metastatic thymic epithelial tumors","volume":"7","author":"Ardeshir-Larijani F","year":"2023","unstructured":"Ardeshir-Larijani F, Schneider BP, Althouse SK,  Clinicogenomic landscape of metastatic thymic epithelial tumors. JCO Precis Oncol 2023;7:e2200465."},{"key":"B45","series-title":"Lung Cancer","first-page":"107324","article-title":"High levels of expression of Trop-2 in thymic epithelial tumors","volume":"184","author":"Yeung V","year":"2023","unstructured":"Yeung V, Zaemes J, Yeh J,  High levels of expression of Trop-2 in thymic epithelial tumors. Lung Cancer 2023;184:107324."},{"key":"B46","series-title":"Clin Lung Cancer","first-page":"180","article-title":"Trop-2 expression and its impact on survival in thymic epithelial tumors: brief report","volume":"25","author":"Ardeshir-Larijani F","year":"2024","unstructured":"Ardeshir-Larijani F, Maniar R, Goyal S,  Trop-2 expression and its impact on survival in thymic epithelial tumors: brief report. Clin Lung Cancer 2024;25:180\u2013185.e1."},{"key":"B47","series-title":"J Thorac Oncol","first-page":"S280","article-title":"P2.14B.03 A phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma and thymic carcinoma","volume":"19(Suppl)","author":"Marks JA","year":"2024","unstructured":"Marks JA, Agarwal S, Ahn J,  P2.14B.03 A phase II parallel arm study of sacituzumab govitecan-hziy in patients with advanced thymoma and thymic carcinoma. J Thorac Oncol 2024;19(Suppl):S280."},{"key":"B48","series-title":"J Clin Oncol","first-page":"8113","article-title":"Comprehensive molecular characterization of thymic epithelial tumors","volume":"42(Suppl)","author":"Kim C","year":"2024","unstructured":"Kim C, Adeyelu TT, Maniar R,  Comprehensive molecular characterization of thymic epithelial tumors. J Clin Oncol 2024;42(Suppl):Abstract 8113."},{"key":"B49","series-title":"Mediastinum","first-page":"AB060","article-title":"AB060. Multiplex immunofluorescence analysis of potential targets in thymic epithelial tumors","volume":"8","author":"Aggarwal V","year":"2024","unstructured":"Aggarwal V, Modepalli S, Ahn J,  AB060. Multiplex immunofluorescence analysis of potential targets in thymic epithelial tumors. Mediastinum 2024;8:AB060."},{"key":"B50","series-title":"Cancers (Basel)","first-page":"2299","article-title":"CD117, BAP1, MTAP, and TdT is a useful immunohistochemical panel to distinguish thymoma from thymic carcinoma","volume":"14","author":"Angirekula M","year":"2022","unstructured":"Angirekula M, Chang SY, Jenkins SM,  CD117, BAP1, MTAP, and TdT is a useful immunohistochemical panel to distinguish thymoma from thymic carcinoma. Cancers (Basel) 2022;14:2299."},{"key":"B51","series-title":"Cancers (Basel)","first-page":"2274","article-title":"EZH2 and POU2F3 can aid in the distinction of thymic carcinoma from thymoma","volume":"15","author":"Naso JR","year":"2023","unstructured":"Naso JR, Vrana JA, Koepplin JW,  EZH2 and POU2F3 can aid in the distinction of thymic carcinoma from thymoma. Cancers (Basel) 2023;15:2274."},{"key":"B52","series-title":"J Transl Med","first-page":"620","article-title":"MTAP loss: a possible therapeutic approach for glioblastoma","volume":"20","author":"Patro CPK","year":"2022","unstructured":"Patro CPK, Biswas N, Pingle SC,  MTAP loss: a possible therapeutic approach for glioblastoma. J Transl Med 2022;20:620."},{"key":"B53","series-title":"Ann Oncol","first-page":"1138","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon J","year":"2024","unstructured":"Rodon J, Prenen H, Sacher A,  First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration. Ann Oncol 2024;35:1138\u20131147."},{"key":"B54","series-title":"J Clin Oncol","first-page":"3011","article-title":"BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007","volume":"43(Suppl)","author":"Arbour KC","year":"2025","unstructured":"Arbour KC, George B, Henry JT,  BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del): clinical update and first report of pharmacokinetics (PK) and pharmacodynamic (PD) analyses from CA240-0007. J Clin Oncol 2025;43(Suppl):Abstract 3011."},{"key":"B55","series-title":"Ann Oncol","first-page":"817","article-title":"Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)","volume":"35","author":"Proto C","year":"2024","unstructured":"Proto C, Ganzinelli M, Manglaviti S,  Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671). Ann Oncol 2024;35:817\u2013826."},{"key":"B56","series-title":"Signal Transduct Target Ther","first-page":"262","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder S","year":"2023","unstructured":"Shyam Sunder S, Sharma UC, Pokharel S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther 2023;8:262."},{"key":"B57","series-title":"Lung Cancer","first-page":"154","article-title":"Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma","volume":"88","author":"Katsuya Y","year":"2015","unstructured":"Katsuya Y, Fujita Y, Horinouchi H,  Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 2015;88:154\u2013159."},{"key":"B58","series-title":"PLoS One","first-page":"e0182665","article-title":"Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors","volume":"12","author":"Arbour KC","year":"2017","unstructured":"Arbour KC, Naidoo J, Steele KE,  Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS One 2017;12:e0182665."},{"key":"B59","series-title":"J Thorac Oncol","first-page":"1204","article-title":"Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma","volume":"13","author":"Owen D","year":"2018","unstructured":"Owen D, Chu B, Lehman AM,  Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma. J Thorac Oncol 2018;13:1204\u20131212."},{"key":"B60","series-title":"J Thorac Oncol","first-page":"500","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda SK","year":"2015","unstructured":"Padda SK, Riess JW, Schwartz EJ,  Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol 2015;10:500\u2013508."},{"key":"B61","series-title":"Eur J Cancer","first-page":"78","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya Y","year":"2019","unstructured":"Katsuya Y, Horinouchi H, Seto T,  Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study. Eur J Cancer 2019;113:78\u201386."},{"key":"B62","series-title":"J Clin Oncol","first-page":"2162","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho J","year":"2019","unstructured":"Cho J, Kim HS, Ku BM,  Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial. J Clin Oncol 2019;37:2162\u20132170."},{"key":"B63","series-title":"Lancet Oncol","first-page":"347","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone G","year":"2018","unstructured":"Giaccone G, Kim C, Thompson J,  Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018;19:347\u2013355."},{"key":"B64","series-title":"J Thorac Oncol","first-page":"483","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone G","year":"2021","unstructured":"Giaccone G, Kim C. Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up. J Thorac Oncol 2021;16:483\u2013485."},{"key":"B65","series-title":"J Immunother Cancer","first-page":"269","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan A","year":"2019","unstructured":"Rajan A, Heery CR, Thomas A,  Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma. J Immunother Cancer 2019;7:269."},{"key":"B66","series-title":"ESMO Open","first-page":"101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard N","year":"2023","unstructured":"Girard N, Ponce Aix S, Cedres S,  Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial. ESMO Open 2023;8:101576."},{"key":"B67","series-title":"Eur J Cancer","first-page":"117","article-title":"Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis","volume":"180","author":"Remon J","year":"2023","unstructured":"Remon J, Villacampa G, Facchinetti F,  Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: a meta-analysis. Eur J Cancer 2023;180:117\u2013124."},{"key":"B68","series-title":"Cell Rep Med","first-page":"100392","article-title":"Molecular predictors of response to pembrolizumab in thymic carcinoma","volume":"2","author":"He Y","year":"2021","unstructured":"He Y, Ramesh A, Gusev Y,  Molecular predictors of response to pembrolizumab in thymic carcinoma. Cell Rep Med 2021;2:100392."},{"key":"B69","series-title":"Ann Rheum Dis","first-page":"150","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen AL","year":"2019","unstructured":"Mammen AL, Rajan A, Pak K,  Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1. Ann Rheum Dis 2019;78:150\u2013152."},{"key":"B70","series-title":"Comput Biol Med","first-page":"109488","article-title":"Unraveling the complexities of immunotherapy for thymic epithelial tumors via bioinformatics and experimental analyses","volume":"185","author":"Zhang G","year":"2025","unstructured":"Zhang G, Yu Q, Chen X,  Unraveling the complexities of immunotherapy for thymic epithelial tumors via bioinformatics and experimental analyses. Comput Biol Med 2025;185:109488."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/4\/article-e257086.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/4\/article-e257086.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/4\/article-e257086.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:08:32Z","timestamp":1775740112000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/4\/article-e257086.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":140,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7086","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}